Chest
Volume 123, Issue 1, January 2003, Pages 209-216
Journal home page for Chest

Reviews
Interferons and Their Application in the Diseases of the Lung

https://doi.org/10.1378/chest.123.1.209Get rights and content

Interferons (IFNs) are a family of cytokine mediators that are critically involved in alerting the cellular immune system to viral infections of host cells. There are three major classes of IFNs, as follows: IFN-α; IFN-β; and IFN-γ. IFNs are being investigated and applied in various respiratory disorders, including interstitial lung diseases, lung cancer, malignant mesothelioma, malignant pleural effusions, and respiratory infections. Recent promising preliminary results concerning patients with idiopathic pulmonary fibrosis who have been treated with IFN-γ1b should prompt the performance of further confirmatory well-designed multicenter trials. IFN-γ is emerging as an important cytokine for use in the treatment of patients with infectious diseases, including multidrug-resistant pulmonary TB. A better understanding of IFN biology, indications, side effect profiles, and toxicity management will aid in optimizing its use in the treatment of patients. The purpose of this article is, therefore, to review the current clinical use of IFNs in the treatment of patients with respiratory diseases.

Section snippets

Biological Effects of IFNs

To understand the mechanism of action of IFNs, it is useful to begin with a brief review of their physiology. IFNs do not normally circulate, are formed constitutively by most cells, and function physiologically by autocrine or paracrine mechanisms.5

The biological effects of IFNs result primarily from the enhanced expression of a group of genes and proteins in responsive cells that are involved in inflammatory and antimicrobial activities. α-IFNs constitute a family of proteins that are

Therapeutic Applications

For the past 40 years, various forms of IFNs have been evaluated as therapy in a number of malignant and nonmalignant diseases. The major oncologic indications for IFNs include melanoma, renal cell carcinoma, AIDS-related Kaposi's sarcoma, follicular lymphoma, hairy cell leukemia, and chronic myelogenous leukemia. IFNs have been increasingly employed in the therapy for patients with viral infections (including hepatitis C and condylomata acuminata) and multiple sclerosis. The therapeutic

Idiopathic Pulmonary Fibrosis

In contrast to normal repair, chronic inflammation in interstitial lung disease promotes fibroproliferation and the deposition of an extracellular matrix reflecting dysregulated and exaggerated tissue repair. The persistent imbalance in the expression of T helper (Th) type 2 cytokines (ie, interleukin [IL]-4 and IL-13) vs Th1 cytokines (IL-2 and IFN-γ) in the lung is a mechanism for the progression of pulmonary fibrosis. IFN-γ is a major Th1 cytokine and possesses profound regulatory activity

Small Cell Lung Cancer

Despite high initial response rates to chemotherapy, most patients with small cell lung cancer (SCLC) relapse shortly after discontinuing therapy, and a cure remains an elusive goal, even for patients with limited-stage disease. For this reason, investigators have turned to the evaluation of alternative treatment strategies for patients with this malignancy. Different IFN preparations were used, but none of the trials showed a significant prolongation of survival.27

IFN has been evaluated in

Malignant Mesothelioma

The natural history of malignant pleural mesothelioma (MPM) remains unchanged with a median survival time for patients of < 12 months. It is resistant to both chemotherapy and radiotherapy.34

The instillation of recombinant human IFN (rhu-IFN)-γ in the pleural cavity has been used with promising results to treat patients with MPM. From the original group of 22 consecutive patients, 19 could be evaluated. Four complete thoracoscopic histopathologic responses and one partial response were observed

Malignant Pleural Effusions

Malignant pleural effusions (MPEs) remain a distressing and symptomatic problem in cancer patients. In one postmortem series,40 MPEs were found in 15% of patients who died with malignancies. MPEs also are one of the leading causes of exudative effusions. Studies40 have demonstrated that 77% of exudative effusions are secondary to a malignancy. Once an MPE is diagnosed, appropriate therapy may provide symptomatic relief and improved quality of life.

MPEs cause severe symptoms in patients with

Respiratory Infections

More than a century after the discovery of Mycobacterium tuberculosis, mycobacterial infections are resurgent. Therapy, which until recently had seemed simple and straightforward, is now complicated by the emergence of drug-resistant organisms and immunocompromised hosts. Multidrug-resistant tuberculosis (MDR-TB) is a serious, life-threatening condition that is associated with a high degree of morbidity and mortality (about 70%).50 Adjuvant cytokines such as IL-2, IFN-γ, IL-12, and

Toxicity

IFNs, when used as a systemic pharmacologic agent, have certain toxic effects. Skin, neurologic, endocrine, and immune toxicities have been reported.3 IFN-α therapy may result in fatigue, fever, weight loss, and appetite loss. In addition, it can induce autoimmune diseases due to its immunomodulatory properties. Furthermore, there are some reports545556 in the literature that describe the development of sarcoidosis associated with IFN-α treatment.

Less commonly, various autoimmune processes have

Conclusion

IFNs are being investigated and applied in patients with various respiratory disorders, including interstitial lung diseases, lung cancer, malignant mesothelioma, malignant pleural effusions, and respiratory infections. Recent promising preliminary results for IPF patients treated with IFN-γ-1b should prompt further confirmatory, well-designed, multicenter trials. IFN-γ is emerging as an important cytokine for use in the treatment patients with infectious diseases, including pulmonary MDR-TB. A

References (58)

  • NJ Vander Els et al.

    Sarcoidosis and IFN-alpha treatment [letter]

    Chest

    (2000)
  • GG Steinmann et al.

    Clinical experiences with interferon-alpha and interferon-gamma

    Int Rev Exp Pathol

    (1993)
  • C Le Page et al.

    Interferon activation and innate immunity

    Rev Immunogenet

    (2000)
  • JU Gutterman

    Cytokine therapeutics: lessons from interferon alpha

    Proc Natl Acad Sci USA

    (1994)
  • E Jonasch et al.

    Interferon in oncological practice: review of interferon biologic clinical applications, and toxicities

    Oncologist

    (2001)
  • C Nathan et al.

    Cytokines in context

    J Cell Biol

    (1991)
  • E De Maeyer et al.

    Type I interferons

    Int Rev Immunol

    (1998)
  • I Gresser

    Antitumour effects of interferons: past, present and future

    Br J Haematol

    (1991)
  • JI Gallin et al.

    Interferon-γ in the management of infectious diseases

    Ann Intern Med

    (1995)
  • RD Granstein et al.

    Gamma-interferon inhibits collagen synthesis in vivo in the mouse

    J Clin Invest

    (1987)
  • HA Jaffe et al.

    Selective inhibition of collagen gene expression in fibroblasts by an interferon-gamma transgene

    Exp Lung Res

    (1999)
  • N Berkman et al.

    Recombinant interferon-alpha2a and interferon-alphaA/D have different effects on bleomycin-induced lung injury

    Respiration

    (2001)
  • G Raghu et al.

    Feasibility of a trial of interferon beta-1A (IFN b-1a) in the treatment of idiopathic pulmonary fibrosis (IPF) [abstract]

    Am J Respir Crit Care Med

    (2001)
  • R Ziesche et al.

    A preliminary study of long-term treatment with interferon gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis

    N Engl J Med

    (1999)
  • G Gurujeyalakshmi et al.

    Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: down-regulation of TGF-beta and procollagen I and III gene expression

    Exp Lung Res

    (1995)
  • L Ulloa et al.

    Inhibition of transforming growth factor-beta/SMAD signaling by the interferon-gamma/STAT pathway

    Nature

    (1999)
  • RM du Bois

    Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis

    N Engl J Med

    (1999)
  • TE King

    Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis [letter]

    N Engl J Med

    (2000)
  • G Raghu et al.
  • Cited by (0)

    View full text